Literature DB >> 23428849

Expression, characterization and inhibition of Toxoplasma gondii 1-deoxy-D-xylulose-5-phosphate reductoisomerase.

Guobin Cai1, Lisheng Deng, Jian Xue, Silvia N J Moreno, Boris Striepen, Yongcheng Song.   

Abstract

The apicomplexan parasite Toxoplasma gondii, the causative agent of toxoplasmosis, is an important human pathogen. 1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) in the non-mevalonate isoprene biosynthesis pathway is essential to the organism and therefore a target for developing anti-toxoplasmosis drugs. In order to find potent inhibitors, we expressed and purified recombinant T. gondii DXR (TgDXR). Biochemical properties of this enzyme were characterized and an enzyme activity/inhibition assay was developed. A collection of 11 compounds with a broad structural diversity were tested against TgDXR and several potent inhibitors were identified with Ki values as low as 48 nM. Analysis of the results as well as those of Escherichia coli and Plasmodium falciparum DXR enzymes revealed a different structure-activity relationship profile for the inhibition of TgDXR.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23428849      PMCID: PMC3602143          DOI: 10.1016/j.bmcl.2013.01.097

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  23 in total

1.  Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria.

Authors:  Sunny Oyakhirome; Saadou Issifou; Peter Pongratz; Fortune Barondi; Michael Ramharter; Jürgen F Kun; Michel A Missinou; Bertrand Lell; Peter G Kremsner
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

Review 2.  The non-mevalonate pathway of isoprenoid precursor biosynthesis.

Authors:  William N Hunter
Journal:  J Biol Chem       Date:  2007-04-18       Impact factor: 5.157

3.  Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase.

Authors:  Guobin Cai; Lisheng Deng; Bartlomiej G Fryszczyn; Nicholas G Brown; Zhen Liu; Hong Jiang; Timothy Palzkill; Yongcheng Song
Journal:  ACS Med Chem Lett       Date:  2012-05-07       Impact factor: 4.345

4.  AFMoC enhances predictivity of 3D QSAR: a case study with DOXP-reductoisomerase.

Authors:  Katrin Silber; Philipp Heidler; Thomas Kurz; Gerhard Klebe
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

Review 5.  The methylerythritol phosphate (MEP) pathway for isoprenoid biosynthesis as a target for the development of new drugs against tuberculosis.

Authors:  C Obiol-Pardo; J Rubio-Martinez; S Imperial
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

6.  Antimalarial and Structural Studies of Pyridine-containing Inhibitors of 1-Deoxyxylulose-5-phosphate Reductoisomerase.

Authors:  Jian Xue; Jiasheng Diao; Guobin Cai; Lisheng Deng; Baisong Zheng; Yuan Yao; Yongcheng Song
Journal:  ACS Med Chem Lett       Date:  2013-02-14       Impact factor: 4.345

Review 7.  Targeting the methyl erythritol phosphate (MEP) pathway for novel antimalarial, antibacterial and herbicidal drug discovery: inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) enzyme.

Authors:  Nidhi Singh; Gweneal Chevé; Mitchell A Avery; Christopher R McCurdy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

Review 8.  Toxoplasmosis.

Authors:  J G Montoya; O Liesenfeld
Journal:  Lancet       Date:  2004-06-12       Impact factor: 79.321

9.  In vitro and in vivo antibacterial activities of FR-31564, a new phosphonic acid antibiotic.

Authors:  Y Mine; T Kamimura; S Nonoyama; M Nishida; S Goto; S Kuwahara
Journal:  J Antibiot (Tokyo)       Date:  1980-01       Impact factor: 2.649

10.  Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake.

Authors:  Amanda C Brown; Tanya Parish
Journal:  BMC Microbiol       Date:  2008-05-20       Impact factor: 3.605

View more
  2 in total

1.  Isoprenoid metabolism in apicomplexan parasites.

Authors:  Leah Imlay; Audrey R Odom
Journal:  Curr Clin Microbiol Rep       Date:  2014-12-01

2.  Triazole-based compound as a candidate to develop novel medicines to treat toxoplasmosis.

Authors:  Katarzyna Dzitko; Agata Paneth; Tomasz Plech; Jakub Pawełczyk; Lidia Węglińska; Piotr Paneth
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.